Clinical Trial Update: Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating subcutaneous barusiban to reduce implantation failure from uterine contractions has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infertility

Drugs mentioned

• Barusiban (barusiban)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Infertility | Phase 2 | Status: COMPLETED